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Abstract
Human African Trypanosomiasis (HAT) is a major public health problem in the Democratic Republic of the Congo (DRC).
Active and passive surveillance for HAT is conducted but may underestimate the true prevalence of the disease. We used
ELISA to screen 7,769 leftover dried blood spots from a nationally representative population-based survey, the 2007
Demographic and Health Survey. 26 samples were positive by ELISA. Three of these were also positive by trypanolysis and/
or PCR. From these data, we estimate that there were 18,592 people with HAT (95% confidence interval, 4,883–32,302) in
the DRC in 2007, slightly more than twice as many as were reported.
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Introduction
Human African trypanosomiasis (HAT) has been reported in
most of sub-Saharan Africa as well as in travelers to the region [1].
Currently, the global prevalence of the disease is uncertain. From
2006 to 2008, there were 7200–8200 reported cases of HAT per
year [2]. However, since HAT occurs in remote areas with poor
health infrastructures, under-reporting is likely. Thus, estimates of
the global burden have been as high as 300,000 [3].
Nearly two-thirds of all reported HAT cases are from the
Democratic Republic of the Congo (DRC). However, the DRC is
a huge country (2.3 million km2) with poor infrastructure and only
2,794 km of paved roads (https://www.cia.gov/library/publica-
tions/the-world-factbook/geos/cg.html). Only 19% of the pre-
sumed at-risk population was screened in 2003 [4]. High
prevalence of HAT was found recently in surveillance ‘‘blind
spots’’ both in the DRC and elsewhere [5]. Thus, the true number
of HAT cases could be much higher than the numbers reported to
the World Health Organization (WHO).
The problem of over- and underestimating the prevalence of
diseases is not unique for HAT. One approach to obtaining
accurate assessments of disease prevalence is through nationally
representative health surveys [6]. Demographic and Health
Surveys (DHS) are a widely used method to obtain nationally
representative data and have been conducted hundreds of times in
developing countries (http://www.measuredhs.com/). Since 2001,
many DHS have included dried blood spots from participants to
be used for a more accurate assessment of HIV seroprevalence.
Seroprevalences determined this way are not subject to selection
biases and are often quite different from results obtained using
sentinel populations such as those who attend antenatal care
clinics. Recently, using these new data, the WHO revised its
estimates of the global prevalence of HIV [7].
In this study, we attempt to obtain a population-based estimate
of HAT prevalence in the DRC. To accomplish this, we screened
7,769 leftover dried blood spots from the 2007 DRC DHS.
Methods
Study subjects
The survey methodology was described previously [8,9]. Briefly,
a 2-stage stratified cluster design based on a national survey was
used to generate nationally representative data on population,
health and social indices. Nine thousand households from 300
randomly selected population-representative geographic clusters
(Fig. 1), were selected for inclusion; all women aged 15 to 49 years
within these households were surveyed, and, in half of the
households, men aged 15 to 59 were surveyed. All men and half of
the women were consented for collection of blood spots. The
specimens were originally collected for the determination of HIV
seroprevalence and were deidentified before we received them.
Our study received ethical approval from the Institutional Review
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Boards of the Kinshasa School of Public Health and the University
of North Carolina.
HAT ELISA
The ELISA for T.b. gambiense was performed as described by
Hasker et al. with some modifications [10]. From each dried blood
spot, two 5 mm diameter disks were punched and eluted in 1 ml
elution buffer. The eluted fraction was separated from the disks
and assayed in duplicate both in the presence and absence of
antigen consisting of a mixture of purified T.b. gambiense LiTat 1.3,
and LiTat 1.5 each at a concentration of 1 mg/ml, coated at
150 ml per well in microtitre plates(Maxisorp, Nunc). ELISA
results were expressed as percent positivity relative to a positive
control serum run in each plate. A result was considered positive if
$ 45%.
Trypanolysis
Immune trypanolysis was performed according to Van
Meirvenne et al. [11] with cloned live populations of T.b. gambiense
Variable Antigen Types (VATs) LiTat1.3 and LiTat 1.5 and one
T.b .rhodesiense VAT ETat 1.2R. The test was adapted for testing
blood impregnated filter paper according to Holland et al. [12].
Briefly, from each dried blood spot, a 6 mm diameter disk was
punched and placed in a well of a flat-bottom microtitre plate
containing 20 ml of guinea pig serum (complement source). The
plate was covered with a lid and put at 4uC on a microtitre plate
shaker for elution. After one hour, 10 ml of a 107 trypanosomes/ml
suspension in guinea pig serum were added to each well, leaving
the filter paper disks in place. The plate was incubated at ambient
temperature and shaken for 30, 60 and 90 minutes. After 90
minutes, the suspension in each well was examined under the
microscope (25610 magnification) for living trypanosomes.
Trypanolysis was considered positive when .50% of the
trypanosomes were lysed. T.b. rhodesiense VAT ETat 1.2R was
used as a control for the absence of non-specific trypanolytic
activity of the test specimens.
HAT PCR
Genomic DNA (gDNA) was extracted from dried blood spots
using the invitrogen Purelink 96 kit (invitrogen, Carlsbad, CA) as
described (Taylor et al, submitted). A TaqManH-MGB real-time
PCR assay targeting the 177 bp satellite repeat was developed,
modeled after a published SYBR Green method [13]. Applied
Biosystems Primer Express Software 3.0 was used to design real-
time PCR primers and FAM-labeled probe to amplify this region
(Table 1). Primer specificity was evaluated through a BLAST
search of the human genome.
After optimizing the assay, each real-time PCR reaction
contained 1 mg of gDNA, ABI’s TaqManH MasterMix (106),
100 nM probe, 300 nM of each primer, and nuclease-free water
to reach a total reaction volume of 25 mL. The real-time PCR
reactions were carried out using an ABI PRISMH 7000 Sequence
Detection System (Applied Biosystems, Inc., Foster City, CA,
USA) under the following conditions: 50uC for 2 minutes, 95uC for
10 min., and 45 cycles of 95uC for 15 seconds and 60uC for 1 min.
Human gDNA extracted from whole blood and nuclease-free
water were used as negative controls. T. b. brucei DNA at 0.1 ng/
mL was used as the positive control. All samples and controls were
run in duplicate or triplicate.
The sensitivity and specificity of this PCR assay was
determined on human samples previously obtained [14]. In-
formed consent from Congolese, Ugandan and Dutch patients
was obtained. The study was approved by the Ethical Committee
of the University of Antwerp (reference number: B3002006603).
Blood was collected from 59 patients, of whom 33 had peripheral
parasites and 26 had CSF parasites only. Control blood was
collected from 50 healthy individuals in Uganda, the DRC, and
the Netherlands.
Statistical analyses
HAT prevalence was determined by calculating the propor-
tion of the 7,769 samples which were positive using the sampling
weights of the DHS survey (in this case the three positive cases
were weighted as2.3). This proportion was then multiplied by
the total mid-year population of the DRC in 2007, estimated by
the Population Reference Bureau to be 62.6 million [15]. The
confidence interval was computed using the standard error of
the percentage calculated by SAS Proc Surveyfreq, which
accounts for sampling weights and clustering of the samples
tested.
Results and Discussion
A total of 7,769 samples were tested by ELISA (Fig. 2). Of these
samples, 26 specimens in 23 sites were found to be positive (data
not shown).
For PCR confirmation of ELISA-positive specimens we
developed a Taqman real-time PCR assay to improve specificity.
Using previously collected samples (not from the DRC DHS set),
this PCR assay was positive in 33% (10/31) of the subjects with
known microscopy-confirmed HAT in peripheral blood samples
and none of the uninfected patients (0/17). Thus, this assay had
low sensitivity but very high specificity.
All 26 ELISA-positive samples were tested by both trypanolysis
and PCR (Fig. 2). Two subjects were positive by trypanolysis with
100% lysis on both LiTat 1.3 and LiTat 1.5 VAT. One of these
trypanolysis-positive specimens was also positive by PCR. In
addition, one trypanolysis-negative subject was positive by PCR,
suggesting a recent infection that had not yet elicited anti-
trypanosomal antibodies.
The other 23 ELISA positive samples which were negative by
PCR and trypanolysis are likely to be false positives. This false
positive rate (23/7766) translates to a very high ELISA test
specificity (99.7% with 95% CI: 99.5–99.9). However, given the
Author Summary
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of many tropical diseases may be inaccurate. In particular,
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(DHS) are a widely used tool to obtain nationally
representative health data and have been conducted
hundreds of times in developing countries, In this report,
we use samples from the 2007 Democratic Republic of the
Congo DHS to estimate the burden of HAT. ELISA tests
were conducted on 7,769 leftover dried blood spots
followed by confirmatory trypanolysis and PCR tests. Our
data suggest that there are approximately 18,592 cases of
Human African Trypanosomiasis (Sleeping Sickness) in the
DRC, close to WHO estimates.
Human African Trypanosomiasis in the DR Congo
www.plosntds.org 2 August 2011 | Volume 5 | Issue 8 | e1246
Figure 1. Map of the 300 sites from which dried blood spots were obtained and where the positive cases were detected.
doi:10.1371/journal.pntd.0001246.g001
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low prevalence of the disease, the ELISA’s positive predictive
value is only 11.5% (95% CI: 4.0–28.9).
All 3 trypanolysis and/or PCR-positive subjects were male and
were HIV-seronegative. Two were co-infected with P. falciparum
[8]. These 3 cases were found in two sites, both of which are in
known endemic regions (Fig. 1).
The overall prevalence of HAT in the DRC was calculated
using standard sampling weights and found to be 29.7 cases/
100,000 persons. Assuming a total population of 62.6 million, this
leads to an estimated 18,592 people with HAT (95% confidence
interval, 4,883–32,302) in the DRC in 2007.
In 2007, the National Trypanosomiasis Control Program
reported 8,162 cases of HAT. Our results suggest that 56% of
actual HAT cases were not detected and therefore not reported
[2]. This is very close to estimates of underreporting used by the
WHO (65–75%) [16].
The estimates obtained here are subject to several limitations.
First, none of the tests are completely sensitive, so cases of HAT
infection could have been missed. Second, HAT is a highly
clustered disease, and it is possible that specific small geographic
regions with high HAT prevalences were not accurately sampled.
Both limitations would have led to understimates of the prevalence
of the disease. Nevertheless, our results provide the first nationally
representative population-based data on the prevalence of this
disease and confirm WHO estimates for under-reporting. This
study also confirm that population-based surveys are useful in
determining the burden of infectious diseases.
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Figure 2. Flow chart showing processing of samples.
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Table 1. Sequences and properties of real-time PCR primers and probe for 177 bp satellite repeat.
Name Sequence %GC Tm (6C)
F Primer GCGCAGTTAACGCTATTATACACA 41.7 59.3
R Primer TTAAACACTAAAGAACAGCGTTGC 37.5 57.6
Probe FAM-CAAGTGTGCAACATTAAATACAAGTG-MGB 35 72
doi:10.1371/journal.pntd.0001246.t001
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